Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies

被引：0
|
作者：
Enrique Grande
Michael C. Kreissl
Sebastiano Filetti
Kate Newbold
Walter Reinisch
Caroline Robert
Martin Schlumberger
Lærke K. Tolstrup
Jose L. Zamorano
Jaume Capdevila
机构：
[1] Hospital Ramón y Cajal,Servicio de Oncología Médica
[2] University Hospital of Wuerzburg,Department of Nuclear Medicine
[3] Central Hospital of Augsburg,Department of Nuclear Medicine
[4] University of Rome “Sapienza”,Department of Internal Medicine and Medical Specialities
[5] Royal Marsden Hospital,Thyroid Unit
[6] Medical University of Vienna,Division of Gastroenterology and Hepatology, Department of Internal Medicine III
[7] University of Paris-Sud,Department of Medical Oncology, Dermatology Unit and INSERM U981, Gustave Roussy Institute
[8] University of Paris-Sud,Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institute
[9] Odense University Hospital,Department of Oncology, Clinical Research Unit
[10] Hospital Ramón y Cajal,Cardiology Service
[11] Vall d’Hebron University Hospital,Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit
[12] Autonomous University of Barcelona,undefined
来源：
Advances in Therapy | 2013年 / 30卷
关键词：
Adverse effects; Antineoplastic agents/adverse effects; Cardiovascular; Dermatology; Medullary thyroid cancer; Medullary thyroid carcinoma; Patient safety; Piperidines/therapeutic use; Protein kinase inhibitors; Thyroid neoplasms/drug therapy; Vandetanib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：945 / 966
页数：21
相关论文
共 50 条
  • [21] Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer
    Hu, Mimi I.
    Elisei, Rossella
    Dedecjus, Marek
    Popovtzer, Aron
    Druce, Maralyn
    Kapiteijn, Ellen
    Pacini, Furio
    Locati, Laura
    Krajewska, Jolanta
    Weiss, Richard
    Gagel, Robert F.
    ENDOCRINE-RELATED CANCER, 2019, 26 (02) : 241 - 250
  • [22] Vandetanib: A novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer
    Ton, GiangThy N.
    Banaszynski, Megan E.
    Kolesar, Jill M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (10) : 849 - 855
  • [23] Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer
    Koehler, Viktoria F.
    Adam, Pia
    Frank-Raue, Karin
    Raue, Friedhelm
    Berg, Elke
    Hoster, Eva
    Allelein, Stephanie
    Schott, Matthias
    Kroiss, Matthias
    Spitzweg, Christine
    THYROID, 2021, 31 (03) : 459 - 469
  • [24] Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
    Robinson, Bruce G.
    Paz-Ares, Luis
    Krebs, Annetta
    Vasselli, James
    Haddad, Robert
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (06): : 2664 - 2671
  • [25] Efficacy and Toxicity of Vandetanib for Advanced Medullary Thyroid Cancer Treatment in Real Life Conditions
    Chougnet, Cecile N.
    Borget, Isabelle
    Tuthyref, Network
    Schlumberger, Martin Jean
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [26] YAP confers resistance to vandetanib in medullary thyroid cancer
    Wang, Huan
    Tang, Jian
    Su, Zhiwei
    BIOCHEMISTRY AND CELL BIOLOGY, 2020, 98 (03) : 443 - 448
  • [27] Progress in Molecular Targeted Therapy for Thyroid Cancer: Vandetanib in Medullary Thyroid Cancer
    Solomon, Benjamin
    Rischin, Danny
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (02) : 119 - 121
  • [28] SAFETY AND EFFICACY OF VANDETANIB AS SYSTEMIC TREATMENT FOR PATIENTS WITH ADVANCED AND PROGRESSIVE MEDULLARY THYROID CANCER (MTC)
    Grande, E.
    Martinez-Trufero, J.
    Arevalo, S.
    Alvarez-Escola, C.
    Beltran, M.
    Jimenez Fonseca, P.
    Alonso-Gordoa, T.
    Dalmau, E.
    Duran, M.
    Gallegos, I.
    Manzano, J. L.
    Mesia, R.
    Pajares, I.
    Fuentes, J.
    Grau, J. J.
    Reig Torras, O.
    Trigo, J. M.
    Pelaez, B.
    Zafon, C.
    Capdevila, J.
    ANNALS OF ONCOLOGY, 2014, 25
  • [29] Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer
    Helton Estrela Ramos
    Fabio Hecht
    Amandine Berdelou
    Isabelle Borget
    Sophie Leboulleux
    Eric Baudin
    Martin Schlumberger
    Endocrine, 2021, 71 : 434 - 442
  • [30] Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer
    Ramos, Helton Estrela
    Hecht, Fabio
    Berdelou, Amandine
    Borget, Isabelle
    Leboulleux, Sophie
    Baudin, Eric
    Schlumberger, Martin
    ENDOCRINE, 2021, 71 (02) : 434 - 442
12345